IndraLab

Statements



reach
"Interestingly, drug sensitivity analysis with IC50 further suggested that docetaxel, epirubicin and inhibitors of PI3K/AKT/mTOR signaling pathway (afuresertib, buparlisib, ipatasertib and dactolisib) are more beneficial to patients in the low-risk group, whereas tyrosine kinase inhibitors (ibrutinib, lapatinib and sapitinib) may better benefit patients in the high-risk group ( Supplementary Figure S6 ).3.9 Sponging ABHD12 and USP41 significantly inhibited the proliferation, invasion and migration of breast cancer cells."